97 related articles for article (PubMed ID: 11234891)
1. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
Kirstein MN; Houghton PJ; Cheshire PJ; Richmond LB; Smith AK; Hanna SK; Stewart CF
Clin Cancer Res; 2001 Feb; 7(2):358-66. PubMed ID: 11234891
[TBL] [Abstract][Full Text] [Related]
2. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
4. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
de Souza PL; Cooper MR; Imondi AR; Myers CE
Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685
[TBL] [Abstract][Full Text] [Related]
5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini G; Pratesi G; De Cesare M; Supino R; Pisano C; Marcellini M; Giordano V; Laccabue D; Lanzi C; Zunino F
Mol Cancer Res; 2003 Oct; 1(12):863-70. PubMed ID: 14573787
[TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
Li ML; Horn L; Firby PS; Moore MJ
Clin Cancer Res; 2001 Jan; 7(1):168-74. PubMed ID: 11205905
[TBL] [Abstract][Full Text] [Related]
10. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts.
Pantazis P; Kozielski AJ; Vardeman DM; Petry ER; Giovanella BC
Oncol Res; 1993; 5(8):273-81. PubMed ID: 8012059
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
[TBL] [Abstract][Full Text] [Related]
13. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.
Cao Z; Kozielski A; Liu X; Wang Y; Vardeman D; Giovanella B
Cancer Res; 2009 Jun; 69(11):4742-9. PubMed ID: 19458069
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
[TBL] [Abstract][Full Text] [Related]
17. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Sparreboom A; de Jonge MJ; Punt CJ; Nooter K; Loos WJ; Porro MG; Verweij J
Clin Cancer Res; 1998 Aug; 4(8):1915-9. PubMed ID: 9717819
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.
Chatterjee A; Digumarti R; Mamidi RN; Katneni K; Upreti VV; Surath A; Srinivas ML; Uppalapati S; Jiwatani S; Subramaniam S; Srinivas NR
J Clin Pharmacol; 2004 Jul; 44(7):723-36. PubMed ID: 15199077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
